Retrophin, Inc: Kevin Kotler’s Broadfin Capital Makes Purchase

February 14, 2018 - By Adrian Erickson

 Retrophin, Inc: Kevin Kotler's Broadfin Capital Makes Purchase

Investors sentiment increased to 1.62 in 2017 Q3. Its up 0.46, from 1.16 in 2017Q2. It is positive, as 12 investors sold Retrophin, Inc. shares while 25 reduced holdings. 20 funds opened positions while 40 raised stakes. 40.07 million shares or 1.15% more from 39.61 million shares in 2017Q2 were reported.

Voya Invest Mngmt Lc holds 0% in Retrophin, Inc. (NASDAQ:RTRX) or 17,905 shares. American Century owns 0.01% invested in Retrophin, Inc. (NASDAQ:RTRX) for 285,875 shares. Fmr Ltd Liability reported 1.83 million shares. Campbell & Co Investment Adviser Ltd Liability Corp holds 0.2% of its portfolio in Retrophin, Inc. (NASDAQ:RTRX) for 10,017 shares. Great West Life Assurance Can reported 0% of its portfolio in Retrophin, Inc. (NASDAQ:RTRX). California Employees Retirement Systems reported 51,001 shares stake. New York-based Consonance Lp has invested 9.65% in Retrophin, Inc. (NASDAQ:RTRX). Thompson Davis & Communications Inc owns 250 shares or 0.01% of their US portfolio. Connecticut-based Aqr Capital Mngmt Limited Liability Company has invested 0% in Retrophin, Inc. (NASDAQ:RTRX). Retail Bank Of Mellon Corp invested in 0% or 443,818 shares. Trexquant Investment L P owns 8,154 shares for 0.05% of their portfolio. Principal Grp Incorporated holds 21,334 shares or 0% of its portfolio. Ameriprise holds 0% or 30,090 shares. Citadel Advsrs Lc owns 410,837 shares. Wells Fargo & Communications Mn owns 58,674 shares.

Since August 16, 2017, it had 0 insider buys, and 1 insider sale for $22,646 activity. REED ELIZABETH E sold $22,646 worth of stock or 942 shares.

The New Kevin Kotler’s Broadfin Capital Holding in Retrophin, Inc

Broadfin Capital reported SC 13G/A form with the SEC for Retrophin, Inc. Access it here: 000091957418001218. As reported by Kevin Kotler’s Broadfin Capital, the filler owns 4.85% or 1,915,991 shares of the Health Care–company.

Retrophin, Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Kevin Kotler’s Broadfin Capital’s positive view for Retrophin, Inc. For a hedge fund managing $1.26 billion in assets and having 10+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Kevin Kotler’s Broadfin Capital’s portfolio is in the sector.

Retrophin, Inc Institutional Sentiment

Filings show 129 investors own Retrophin, Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 1381020. 34181337 were owned by these investors. 26 funds opened new Retrophin, Inc stakes, 58 increased positions. There were 18 that closed positions and 37 reduced them.

6 investors had the stock in their top 10. Some are: Consonance Capital Management Lp, Broadfin Capital Llc, Perceptive Advisors Llc..

Kevin Kotler Broadfin Capital Llc is an investor bullish on Retrophin, Inc, owning 2609790 shares as of Q3 2015 for 2.95% of its portfolio. Joseph Edelman Perceptive Advisors Llc owns 2647080 shares or 4.29% of its portfolio. CA Ecor1 Capital Llc have 9.29% of its portfolio for 1007660 shares. Further, Lombard Odier Asset Management Usa Corp reported stake worth 2.19% of its portfolio. The NY Consonance Capital Management Lp owns 3450323 shares. Retrophin, Inc is 9.84% of its portfolio.

Business Profile

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

SEC Form 13G.

Kevin Kotler’s Broadfin Capital website.

Analysts await Retrophin, Inc. (NASDAQ:RTRX) to report earnings on March, 7. After $-0.46 actual EPS reported by Retrophin, Inc. for the previous quarter, Wall Street now forecasts -56.52 % EPS growth.

The stock increased 3.77% or $0.79 during the last trading session, reaching $21.74. About 277,561 shares traded or 18.46% up from the average. Retrophin, Inc. (NASDAQ:RTRX) has risen 4.93% since February 14, 2017 and is uptrending. It has underperformed by 11.77% the S&P500.

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. The company has market cap of $854.53 million. The Company’s marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. It currently has negative earnings. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc , a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis.

Retrophin, Inc. (NASDAQ:RTRX) Ratings Coverage

Among 4 analysts covering Retrophin (NASDAQ:RTRX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Retrophin has $44 highest and $25 lowest target. $39.33’s average target is 80.91% above currents $21.74 stock price. Retrophin had 7 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Retrophin, Inc. (NASDAQ:RTRX) earned “Buy” rating by BMO Capital Markets on Friday, October 6. The stock of Retrophin, Inc. (NASDAQ:RTRX) has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. The firm earned “Buy” rating on Tuesday, November 7 by BMO Capital Markets. The rating was initiated by JMP Securities on Monday, November 2 with “Mkt Outperform”. On Wednesday, August 12 the stock rating was downgraded by Zacks to “Buy”.

Another recent and important Retrophin, Inc. (NASDAQ:RTRX) news was published by Streetinsider.com which published an article titled: “Form 4 Retrophin, Inc. For: Feb 08 Filed by: Clague Laura” on February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: